A. A. Lyulko

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

Robert J. Motzer, Dmitry Nosov, Tim Eisen et al. · Journal of Clinical Oncology · 2012 · 95 citations

Medicine, Oncology, Pharmacology +17

Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC)

Pankaj Bhargava, B. Esteves, Dmitry Nosov et al. · Journal of Clinical Oncology · 2009 · 31 citations

Medicine, Oncology, Pharmacotherapy +16

Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

Pankaj Bhargava, B. Esteves, Mohammed Al-Adhami et al. · Journal of Clinical Oncology · 2010 · 24 citations

Medicine, Oncology, Pharmacotherapy +14